# A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

> **NCT00679341** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 137 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab emtansine [Kadcyla]
- **DRUG:** Trastuzumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00679341
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-11
- **Final completion:** 2012-05
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2014-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679341, "A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00679341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*